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Leishmanial proteins can correct human mitochondrial 
mutations
The kinetoplastid parasites are a class of fl agellate protozoan microorganisms. They are characterized by 
the possesion, within their single mitochondrion, of a DNA-containing granule known as the kinetoplast. 
Trypanosomatids, which constitute an Order among kinetoplastids, contain parasitic genera that are major 
agents of human disease – for example, sleeping sickness and Chagas disease (caused by species of 
Trypanosoma) and leishmaniasis (caused by species of Leishmania). A recent publication by Mahata et al 
(2006) advances the surprising possibility that proteins from Leishmania may in fact be useful for treating 
human disease – specifi cally, for curing disease originating from certain mitochondrial defects.
Mitochondria are the energy-producing symbiotic organelles that are present in the cells of most 
eukaryotes. In general, they are essential for the survival of the cell. Testifying to their independent 
ancestry, they contain their own DNA. The human mitochondrial genome is a small (16,569 bp) circular 
DNA molecule encoding 13 proteins required for oxidative phosphorylation, 22 tRNAs and 2 rRNAs. 
When mutated, it can lead to various neurological and muscular disorders that can be identifi ed by their 
maternal inheritance pattern. Deletions and missense mutations in mitochondrial genes have been mapped 
for diseases such as Leber’s hereditary optic neuropathy (LHON), myoclonic epilepsy associated with 
ragged red muscle fi bres (MERRF, indicative of mitochondrial proliferation in muscle), Kearns-Sayre 
syndrome (KSS) and a neurological syndrome leading to retinitis pigmentosa, ataxia, seizures and 
dementia. In most of these diseases, the affected individual’s cells are heteroplasmic, meaning that they 
contain a mixture of normal and mutant mitochondria. The severity of the disease is affected by the ratio 
of mutant to normal mitochondria (Lander and Lodish 1990). 
It turns out that mitochondria encode only a small subset of the proteins and RNAs that they require 
for their functioning. This means that they need to import many nuclear genome-encoded proteins and 
RNAs. However, in the case of human mitochondria, all the tRNAs required for making mitochondrial 
proteins are encoded by the mitochondrial genome itself. Therefore human mitochondria do not normally 
import tRNAs. In contrast, trypanosomatid genomes do not encode any mitochondrial tRNA genes at all. 
Their evolution has resulted in a condition in which they import (from the host) all the tRNAs that are 
required for translation by the kinetoplastid. In trypanosomatids, this typically parasitic property of a loss 
of function is accompanied by the co-evolution of an RNA import complex (RIC), a large multi-subunit 
aggregate containing several tRNA binding proteins. 
Myoclonic epilepsy is associated with point mutations in human mitochondrial DNA at positions 8344 
and 8356. These alter the tRNALys TψC loop and stem respectively (Shoffner et al 1990; Masucci et al 
1995). By making use of cytoplasmic hybrids or ‘cybrids’, Masucci et al (1995) demonstrated that both 
mutations result in aberrant or ineffi cient mitochondrial translation and lead to the same biochemical and 
phenotypic alterations. Subsequent work suggested that one might try to rescue human mitochondrial 
defects in two ways. Goswami et al (2003) discovered that human tRNALys was imported by the 
Leishmania mitochondrion. Working with cell cultures, Kolesnikova et al (2004) were able to functionally 
complement the human mitochondrial A8344G tRNALys mutation by inducing defective mitochondria to 
import yeast tRNALys . These experiments showed that tRNAs from different species could be effi ciently 
interchanged and loss of mitochondrial function restored. However, the methods suffered from too many 
diffi culties – for example, low effi ciency and toxicity caused by the transfection vehicle – to make it 
possible to think of modifying them for therapeutic purposes.
The latest report by Mahata et al (2006) makes use of an ingenious method to overcome the low 
effi ciency and toxicity of transfection vehicles: they introduce the RNA import complex (RIC) of 
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Leishmania into human cells. The exogenously added RIC was taken up by a caveolin-1 dependant 
pathway and subsequently facilitated the import of cytosolic tRNAs in cybrids that harboured mutants 
of human mt-tRNALys . Using siRNA targeted to caveolin and clathrin, they show that Leishmania RIC is 
internalized specifi cally by the caveolin-1 pathway and not by the clathrin-mediated endocytotic pathway. 
After having demonstrated the uptake of RIC in cybrids, they tested the hypothesis that the RIC could 
cause tRNA to be imported in whole cells. Untreated MERRF mitochondria show a general reduction 
in mitochondrial protein synthesis and accumulation of aberrant translational products. Treatment with 
RIC completely restored the protein synthesis profi le to wild-type levels and suppressed the formation of 
aberrant products. Additionally, as a consequence of its tRNA import by the RIC, the respiratory activity 
of mitochondria was restored. The recovery of wild-type functions was stable for at least 4 generations in 
these cells; the authors argue that this could be due to dilution of the RIC over time.
The observations of Mahata et al (2006) have opened up interesting possibilities for the therapy of 
inherited mitochondrial diseases in humans. Many years ago Lander and Lodish (1990) drew attention 
to the inherent diffi culties to be overcome in thinking of gene therapy for mitochondrial diseases. The 
application of protozoan proteins to correct human disorders was surely unforeseen both by human 
geneticists and protozoologists. 
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